Small Cap Feast

Small Cap Feast – 01 April 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 903

Total number of AIM Companies trading: 833*
* As at 22 March 2019

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): 89*

Total number of NEX Growth Market Companies trading: 87*
* As at 22 March 2019

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): 161*

Total number of Standard List Companies trading: 141*
* As at 22 March 2019

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

Main Market (Premium)

US Solar Fund, a newly-established investment company focused on investing in solar power assets mainly in the US, looking to raise $250m at $1. Expected 16 April

Network International Holdings—Pleading enabler of digital commerce across the Middle East and Africa  region, operating across over 50 highly underpenetrated payment markets that contain a total population of 1.5 bn. 2018 rev $298m, underlying EBITDA $152m.  Due April. No new funds to be raised. Secondary sell down. Targeting 25% of at least 25%.

AIM

Techniplas –global  producer and support services company providing highly engineered and technically complex components, making the supply chain to original equipment manufacturers more efficient.  FYDec17 rev $515m.

Breakfast Buffet

Mosman Oil & Gas (MSMN.L) 0.28p £1.72m

“The oil exploration, development and production company, advises that the Stanley-2 well in Texas has completed drilling at 5,000 feet. Next operations will be electric logging and running casing. The well encountered the pre-drill target of Eocene aged sands (which includes the Yegua sands). A period of evaluation will now commence, prior to bringing the well on production.

Stanley-2 is part of the Strategic Alliance with the privately-owned Baja Oil & Gas, LLC. Stanley-2 is designed to penetrate several Eocene sand targets up-dip from Stanley-1, to optimise the oil production and recovery from these zones identified on 3D seismic and penetrated by Stanley-1.”

Immupharma (IMM.L) 10.66p £16.14m

Update in relation to its discussions with Incanthera on its Nucant cancer programme.

The Company and Incanthera have to date not concluded the Definitive Licence Agreement. The exclusivity period has now expired and ImmuPharma is free, should it wish, to discuss collaborations with other parties for the Nucant cancer programme. Notwithstanding the expiry of the exclusivity period, discussions with Incanthera are continuing in good faith for a broader collaboration.

 

Codemasters Group (CDM.L) 244p £333.1m

FYMar19 trading update from the award winning British video game developer and publisher specialising in high quality racing games.

“The Board is pleased to announce that trading through the second half of the year has continued to be strong. The Company anticipates reporting FY19 revenues of c.£71m, Adjusted EBITDA of c.£18.5m and gross cash of c.£18.4m as at 31 March 2019.

The Adjusted EBITDA is ahead of market expectations and follows the Company’s joint development agreement with Netease  announced on 8 Jan 2019, and the successful launch of DiRT Rally 2.0 on 26 Feb 2019.”

Amino Technologies (AMO.L) 91.5p £61.91m

The global provider of media and entertainment technology solutions to network operators, announced that its next-generation devices have received Google Operator Tier Android certification and will be showcased at NAB show 2019.

AminoOS, the Company’s software solution for deploying and managing connected devices, powers Amino’s next generation devices. This gives pay-TV operators the device agility to customize and brand an advanced user interface via an Android TV deployment, as well as access to all the latest features and functionality including more than 150 premium over-the-top (OTT) apps.

 

Iomart (IOM.L) 349p £378.21m

FY Mar 19 update from the cloud computing Company.

The Group expects to report revenue growing to approximately £104m (FY2018: £97.7m), adjusted EBITDA of approximately £42.2m (FY2018: £39.8m) and adjusted PBT of approximately £25.3m (FY2018: £24m). Over the last 12 months we have reinvigorated our sales and marketing function to ensure we are best placed to capture the full market opportunity. The early benefits of this effort started to flow through in the second half of the financial year with an increase in new lead generation from both new and existing customers. This has delivered a strong finish to the year with a significantly larger pipeline of prospects than this time last year and we enter the new financial year with confidence.

 

Two Shields (TSI.L) 0.11p £2.19m

The “investment company with a strategy to build a high quality portfolio of investments in fast growing and scalable digital and technology enabled businesses, provided an update regarding its immediate actions aimed at rebuilding value for shareholders following its recent strategic review.

A new and experienced senior team has been assembled in line with the Company’s updated strategy. The team will seek to apply its extensive and highly complementary expertise and knowledge to identifying, assessing and executing investment opportunities that have the potential to deliver attractive returns to shareholders.”

$300k convertible  into Brandshield Complete.

Further £100,000 in to WeShop by way of an equity investment.

 

Churchill Mining (NEX:CHL) SUSPENDED

Intention to appoint administrators. “The notice of appointment follows the ICSID Annulment Committee decision to dismiss the Company’s Annulment Application. Churchill had previously filed claims against the Republic of Indonesia at the International Centre for Settlement of Investment Disputes (for damages arising out of the unlawful revocation of the mining licenses that made up the East Kutai Coal Project  by the head of the East Kutai’s Regency Government, Mr Isran Noor.

In accordance with statutory requirements, the Board intends to appoint administrators after 5 business days, at which point the Company expects to request the cessation of trading in the Company’s shares on the NEX Exchange. A corresponding announcement will be made in due course.”

 

Warehouse REIT (WHR.L) 104p £170.98m

The specialist warehouse investor, has exchanged contracts to acquire a 53,000 sq ft single-let industrial unit in Wakefield for £4.2m, reflecting a net initial yield of 6.3%. It follows the announcement on 29 March 2019 that the Company had raised £76.48m of equity, which along with leverage, provides it with over £120m of investment firepower to deploy into a near term pipeline of opportunities, as it looks to benefit from the favourable investment backdrop for the single-let and multi-let warehouse sector.

Wakefield 41 is Yorkshire’s premier distribution location which is home to Coca Cola, Morrisons and Menzies amongst a number of other national and international businesses.

 

Independent Oil & Gas (IOG.L) 11.62p £21.83m

Conditional £16.6m fundraising at 10p. Restructuring of existing arrangements with London Oil & Gas Limited. £7.1m of debt extended 12 months. £1.64m of interest. Warrants  extended.

The primary use of the proceeds pursuant to the Placing will be to allow the Company to drill its appraisal well at Harvey, expected to spud in mid-2019, at a total remaining cost of approximately £9.6m.

In addition, approximately £2.5m of the proceeds of the Placing will be used to fund continued work on a field development plan for the Goddard gas field.

The remaining proceeds of the Placing and any proceeds of the Open Offer and the Subscription will be used to fund the Company’s working capital requirements to the end of 2019 and ongoing project management cost.

 

Renalytix AI (RENX.L) 147.5p £76.69m

The developer of artificial intelligence-enabled diagnostics for kidney disease, announced publication of results generated by a confirmation study.

Study demonstrated that combining the Company’s sTNFR 1, sTNFR2 and KIM-1 biomarkers with the analysis of data from de-identified electronic health records can significantly improve prediction of rapid kidney function decline (“RKFD”) compared to widely used approaches

A total of 1,369 patients were part of the study, including 871 patients with Type 2 diabetes and 498 patients of African ancestry

The study incorporating a “random forest” inference approach to machine learning significantly outperformed standard clinical metrics for prediction of patients experiencing RKFD

The study also demonstrated a high negative predictive value can be achieved for approximately 1/3 of patients with existing kidney disease who are unlikely to experience RKFD

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.